Publication date context: February 11, 2026. A clinical trial testing Spatial StimelMD SSMD for upper limb neuromotor impairments has begun recruitment. The study is sponsored by Motion Informatics LTD and lists Functional Electrical Stimulation as a comparator in addition to SSMD as the investigational device. The study targets adults with stroke, upper limb impairment, hemiparesis, spinal cord injury, or traumatic brain injury. The trial is registered on ClinicalTrials.gov under NCT07404761 and is currently recruiting. This regulatory update summarizes what is known from the source text and its implications for safety and potential future use of SSMD in this patient population. In this article navigation will help readers jump to the sections on device description, trial design, safety signals, and regulatory context.
What is Spatial StimelMD and why is it being tested?
Spatial StimelMD SSMD is the device studied for safety and effectiveness in upper limb neuromotor impairment. The current record lists stroke and other injuries as the underlying conditions, including upper limb impairment, hemiparesis, spinal cord injury, and traumatic brain injury. The sponsor is Motion Informatics LTD. Functional Electrical Stimulation is listed as a comparator in addition to SSMD as the investigational device.
What is the trial design and who is included?
Interventions are SSMD and Functional Electrical Stimulation. Conditions of interest include stroke, upper limb impairment, hemiparesis, spinal cord injury, and traumatic brain injury. Sponsor is Motion Informatics LTD. Recruitment status is Recruiting, per ClinicalTrials.gov record NCT07404761. The public trial page is linked in the source.
What interventions are tested?
The study lists Spatial StimelMD and Functional Electrical Stimulation as the devices under evaluation. The source text does not disclose experimental endpoints or sample size.
What conditions are included?
Participants may have stroke, upper limb impairment, hemiparesis, spinal cord injury, or traumatic brain injury as per the source text.
What safety and efficacy signals are sought?
The record describes the trial as a safety and effectiveness assessment of SSMD in subjects with upper limb neuromotor impairment. No results are provided in the source text. The recruitment status indicates ongoing enrollment.
What outcomes are described?
Specific outcome measures are not described in the provided source text. Availability of data will depend on future trial results.
What does this mean for regulators and operators?
Regulatory readers will note that a new device SSMD is under evaluation for upper limb neuromotor impairment. The sponsor is Motion Informatics LTD, and the trial compares SSMD with FES. Active recruitment and a public record on ClinicalTrials.gov provide transparency and a potential basis for future regulatory discussions on safety and performance claims.
What are next steps for participants and readers?
Next steps depend on recruitment progress and data availability. Regulators will assess safety and efficacy signals as they emerge. Stakeholders should monitor updates on the ClinicalTrials.gov page and from Motion Informatics LTD for milestones.
- What is Spatial StimelMD SSMD
- Who sponsors this trial
- What conditions are included
- Where can I find the public trial record
In summary, Spatial StimelMD is under evaluation in a regulatory context for upper limb neuromotor impairment. The trial status shows recruitment and no results are reported yet. Stakeholders should await data and any future regulatory submissions.
This information is intended for professionals and is not legal advice. It does not constitute regulatory guidance or a decision. For formal guidance, consult the applicable authorities.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07404761?term=medical+device